Wondering if Repligen at around US$113 is starting to look interesting on price, or if the recent weakness is telling you to be cautious about its value? The stock closed at US$113.11, with returns of ...

Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming ...

NEW YORK (Reuters) -Repligen, a provider of drug manufacturing equipment, has approached Maravai LifeSciences Holdings, a vaccine capping reagent vendor that has a market value of about $2.5 billion, ...

Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2026 financial results on Tuesday, May 5, 2026. The Company will issue a press release before the ...

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) in Q4 CY2024, but sales were flat year on year at $167.5 million. The company’s outlook for the full year was close to analysts’ ...

View Repligen Corporation RGEN stock quote prices, financial information, real-time forecasts, and company news from CNN.

FOOTNOTES FOR ALL TABLES ABOVE (amounts in thousands): (1) In July 2023, we began restructuring activities to simplify and streamline our organization and strengthen the overall effectiveness of our ...

Repligen Q4 EPS of $0.44 beat the $0.41 estimate, while revenue of $167.55 million was in line with forecasts. 2025 sales guidance set at $685 million–$710 million ...